DRUG · Mapped RxNorm record
Neratinib
Normalized identity: neratinibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer
NCT05154396
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedNeratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HER2-positive Breast Cancerunresolved
Interventions
NeratinibDRUG · verified · RxNorm: neratinib
Sponsors & collaborators
Chinese Academy of Medical Scienceslead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05154396 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.